Login / Signup

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

M Elaine HusniAtul A DeodharSergio SchwartzmanSoumya D ChakravartyElizabeth C HsiaJocelyn H LeuYiying ZhouKim H LoArthur Kavanaugh
Published in: Arthritis research & therapy (2022)
gov , NCT02186873 . Registered on July 10, 2014.
Keyphrases
  • ankylosing spondylitis
  • rheumatoid arthritis
  • disease activity
  • high dose
  • systemic lupus erythematosus
  • interstitial lung disease
  • phase iii
  • low dose
  • open label